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Summary
Background
Trial findings show cognitive behaviour therapy (CBT) and graded exercise therapy (GET) can be
effective treatments for chronic fatigue syndrome, but patients' organisations have reported that these
treatments can be harmful and favour pacing and specialist health care. We aimed to assess
effectiveness and safety of all four treatments.
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Methods
In our parallel-group randomised trial, patients meeting Oxford criteria for chronic fatigue syndrome
were recruited from six secondary-care clinics in the UK and randomly allocated by computer-
generated sequence to receive specialist medical care (SMC) alone or with adaptive pacing therapy
(APT), CBT, or GET. Primary outcomes were fatigue (measured by Chalder fatigue questionnaire score)
and physical function (measured by short form-36 subscale score) up to 52 weeks after randomisation,
and safety was assessed primarily by recording all serious adverse events, including serious adverse
reactions to trial treatments. Primary outcomes were rated by participants, who were necessarily
unmasked to treatment assignment; the statistician was masked to treatment assignment for the
analysis of primary outcomes. We used longitudinal regression models to compare SMC alone with
other treatments, APT with CBT, and APT with GET. The final analysis included all participants for
whom we had data for primary outcomes. This trial is registered at http://isrctn.org, number
ISRCTN54285094.
Findings
We recruited 641 eligible patients, of whom 160 were assigned to the APT group, 161 to the CBT group,
160 to the GET group, and 160 to the SMC-alone group. Compared with SMC alone, mean fatigue
scores at 52 weeks were 3·4 (95% CI 1·8 to 5·0) points lower for CBT (p=0·0001) and 3·2 (1·7 to 4·8)
points lower for GET (p=0·0003), but did not differ for APT (0·7 [−0·9 to 2·3] points lower; p=0·38).
Compared with SMC alone, mean physical function scores were 7·1 (2·0 to 12·1) points higher for CBT
(p=0·0068) and 9·4 (4·4 to 14·4) points higher for GET (p=0·0005), but did not differ for APT (3·4
[−1·6 to 8·4] points lower; p=0·18). Compared with APT, CBT and GET were associated with less
fatigue (CBT p=0·0027; GET p=0·0059) and better physical function (CBT p=0·0002; GET p<0·0001).
Subgroup analysis of 427 participants meeting international criteria for chronic fatigue syndrome and
329 participants meeting London criteria for myalgic encephalomyelitis yielded equivalent results.
Serious adverse reactions were recorded in two (1%) of 159 participants in the APT group, three (2%) of
161 in the CBT group, two (1%) of 160 in the GET group, and two (1%) of 160 in the SMC-alone group.
Interpretation
CBT and GET can safely be added to SMC to moderately improve outcomes for chronic fatigue
syndrome, but APT is not an effective addition.
Funding
UK Medical Research Council, Department of Health for England, Scottish Chief Scientist Office,
Department for Work and Pensions.
Introduction
Chronic fatigue syndrome is characterised by chronic disabling fatigue in the absence of an alternative
diagnosis.  Myalgic encephalomyelitis is thought by some researchers to be the same disorder and by
others as different with separate diagnostic criteria.  The prevalence of chronic fatigue syndrome is
between 0·2% and 2·6% worldwide, dependent on the definition used.  Prognosis is poor if untreated.
Specific therapies can improve outcomes. The UK National Institute for Health and Clinical Excellence
(NICE) recommend cognitive behaviour therapy (CBT) and graded exercise therapy (GET).  Although
this recommendation was supported by systematic reviews,  supporting evidence remains restricted
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to small trials.  Surveys by patients' organisations in the UK have reported that CBT and GET are
sometimes harmful, and have recommended pacing and specialist health care.
We designed the pacing, graded activity, and cognitive behaviour therapy: a randomised evaluation
(PACE) trial  to compare pacing, defined as adaptive pacing therapy (APT), CBT, and GET, when
added to specialist medical care (SMC) with SMC alone. We sought evidence of benefit and harm. We
also aimed to compare APT against CBT and GET and examine these comparisons in subgroups
satisfying different diagnostic criteria for chronic fatigue syndrome and myalgic encephalomyelitis. We
postulated that CBT and GET would be more effective than would APT and SMC, and that APT would
be more effective than SMC alone.
Methods
Study design and participants
PACE was a parallel, four group, multicentre, randomised trial, with outcomes assessed up to 52 weeks
after randomisation for patients with chronic fatigue syndrome.  We recruited 641 participants from
consecutive new outpatients attending six specialist chronic fatigue syndrome clinics in the UK
National Health Service between March 18, 2005, and Nov 28, 2008, and completed outcome data
collection in January, 2010.
Several diagnostic criteria exist for chronic fatigue syndrome and myalgic encephalomyelitis.  We
selected participants in accordance with Oxford criteria for chronic fatigue syndrome.  These criteria
require fatigue to be the main symptom, accompanied by significant disability, in the absence of an
exclusionary medical or psychiatric diagnosis (psychosis, bipolar disorder, substance misuse, an organic
brain disorder, or an eating disorder).  All participants were medically assessed by the specialist clinic
doctors to exclude alternative diagnoses.  Research assessors used the structured clinical interview
from the Diagnostic and Statistical Manual of Mental Disorders IV to diagnose exclusionary and
comorbid psychiatric disorders (ie, mood and anxiety disorders).
Other eligibility criteria consisted of a bimodal score of 6 of 11 or more on the Chalder fatigue
questionnaire  and a score of 60 of 100 or less on the short form-36 physical function subscale.  11
months after the trial began, this requirement was changed from a score of 60 to a score of 65 to
increase recruitment.
We excluded patients who were younger than 18 years or at significant risk of self-harm, unable to
attend hospital appointments, unable to speak and read English, had medical needs that made
participation inappropriate, had previously received a trial treatment for their present illness at a PACE
trial clinic (we initially excluded anyone who had received a trial treatment, but found the nature of
treatment given elsewhere hard to establish).  Participants were also assessed by international criteria
for chronic fatigue syndrome,  requiring four or more accompanying symptoms, and the London
criteria  for myalgic encephalomyelitis (version 2), requiring postexertional fatigue, poor memory and
concentration, symptoms that fluctuate, and no primary depressive or anxiety disorder (interpreted as
an absence of any such disorder).
We obtained separate written informed consent for assessment and entry into the trial. The West
Midlands Multicentre Research Ethics Committee (MREC 02/7/89) approved the study.
Randomisation and masking
Participants were allocated to treatment groups through the Mental Health and Neuroscience Clinical
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Trials Unit (London, UK), after baseline assessment and obtainment of consent. A database
programmer undertook treatment allocation, independently of the trial team. The first three
participants at each of the six clinics were allocated with straightforward randomisation. Thereafter
allocation was stratified by centre, alternative criteria for chronic fatigue syndrome  and myalgic
encephalomyelitis,  and depressive disorder (major or minor depressive episode or dysthymia),  with
computer-generated probabilistic minimisation. Once notified of treatment allocation by the Clinical
Trials Unit, the research assessor informed the participant and clinicians. One therapist was available
for every therapy per centre, with few exceptions. Specialist medical care doctors were allocated by
convenience. As with any therapy trial, participants, therapists, and doctors could not be masked to
treatment allocation and it was also impractical to mask research assessors. The primary outcomes
were rated by participants themselves. The statistician undertaking the analysis of primary outcomes
was masked to treatment allocation.
Procedures
Panel 1 shows treatment strategies and webappendix p 1 shows characteristics of treating clinicians.
Therapy leaders (one per therapy and with substantial experience in treatment of chronic fatigue
syndrome) trained therapists until they were deemed competent to provide trial treatments. Individual
therapy supervision was provided once every month, and by group every 3 months.  All treatment
sessions were recorded acoustically. Two independent clinicians, who were masked to allocated
treatment, rated recordings of a randomly chosen sample of the tenth (or nearest) session of 62 (13%)
of 480 participants (two sessions for every therapist, when available) for therapy type, adherence to the
manual (7-point Likert scale), and therapeutic alliance between therapist and participant (7-point
Likert scale). These clinicians recorded when masking had failed, such as when the treatment was
mentioned by name. All doctors received training in specialist medical care, and we assessed
competence and monitored manual adherence for most. We defined ten sessions of therapy or three
sessions of specialist medical care alone as adequate treatment for the per-protocol analysis. We
recorded number of treatment sessions attended, active withdrawals from treatment, additional
treatments received, and dropouts from follow-up.
Panel 1
Treatments provided
Overview
We standardised treatments by provision of manuals for doctors, therapists, and participants. At
least three sessions of specialist medical care were offered to participants during the 12 months, and
more were offered if clinically indicated. Up to 14 therapy sessions were offered during the first 23
weeks; the first four were once a week and subsequently they were once every 2 weeks. An
additional booster session was offered at 36 weeks. No other additional sessions were offered. Most
treatments were delivered face-to-face but some were provided by telephone. Treatment was
provided individually although participants could be accompanied if they wanted.
Specialist medical care (SMC)
SMC was provided by doctors with specialist experience in chronic fatigue syndrome (webappendix
p 1). All participants were given a leaflet explaining the illness and the nature of this treatment. The
manual was consistent with good medical practice, as presently recommended.  Treatment
consisted of an explanation of chronic fatigue syndrome, generic advice, such as to avoid extremes
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of activity and rest, specific advice on self-help, according to the particular approach chosen by the
participant (if receiving SMC alone), and symptomatic pharmacotherapy (especially for insomnia,
pain, and mood).
Adaptive pacing therapy (APT)
APT was based on the envelope theory of chronic fatigue syndrome.  This theory regards chronic
fatigue syndrome as an organic disease process that is not reversible by changes in behaviour and
which results in a reduced and finite amount (envelope) of available energy. The aim of therapy was
to achieve optimum adaptation to the illness, hence APT. This adaptation was achieved by helping
the participant to plan and pace activity to reduce or avoid fatigue, achieve prioritised activities and
provide the best conditions for natural recovery.  Therapeutic strategies consisted of
identifying links between activity and fatigue by use of a daily diary, with corresponding
encouragement to plan activity to avoid exacerbations, developing awareness of early warnings of
exacerbation, limiting demands and stress, regularly planning rest and relaxation, and alternating
different types of activities, with advice not to undertake activities that demanded more than 70% of
participants' perceived energy envelopes. Increased activities were encouraged, if the participant felt
able, and as long as they did not exacerbate symptoms.
Because this treatment had not been described in a manual, we created and piloted manuals for
therapists and patients on the basis of previous descriptions,  what pilot patients and clinicians
reported as helpful, and with the advice of experienced therapists. Westcare and Action for ME
helped in the design of the therapy and endorsed the final manuals.  APT was provided by
occupational therapists (webappendix p 1).
Cognitive behaviour therapy (CBT)
CBT was done on the basis of the fear avoidance theory of chronic fatigue syndrome. This theory
regards chronic fatigue syndrome as being reversible and that cognitive responses (fear of engaging
in activity) and behavioural responses (avoidance of activity) are linked and interact with
physiological processes to perpetuate fatigue. The aim of treatment was to change the behavioural
and cognitive factors assumed to be responsible for perpetuation of the participant's symptoms and
disability. Therapeutic strategies guided participants to address unhelpful cognitions, including fears
about symptoms or activity by testing them in behavioural experiments. These experiments
consisted of establishing a baseline of activity and rest and a regular sleep pattern, and then making
collaboratively planned gradual increases in both physical and mental activity. Furthermore,
participants were helped to address social and emotional obstacles to improvement through
problem-solving. Therapy manuals were based on manuals used in previous trials.  CBT was
delivered mainly by clinical psychologists and nurse therapists (webappendix p 1).
Graded exercise therapy (GET)
GET was done on the basis of deconditioning and exercise intolerance theories of chronic fatigue
syndrome. These theories assume that the syndrome is perpetuated by reversible physiological
changes of deconditioning and avoidance of activity. These changes result in the deconditioning
being maintained and an increased perception of effort, leading to further inactivity. The aim of
treatment was to help the participant gradually return to appropriate physical activities, reverse the
deconditioning, and thereby reduce fatigue and disability. Therapeutic strategies consisted of
establishment of a baseline of achievable exercise or physical activity, followed by a negotiated,
incremental increase in the duration of time spent physically active. Target heart rate ranges were
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We undertook assessments at baseline and 12 weeks (mid-therapy), 24 weeks (post-therapy), and 52
weeks after randomisation. Primary outcomes were also assessed at the time of dropouts, and used
when no other outcome data were available. The research assessors did the assessments, usually face-
to-face in clinic. Most measures were self-rated by the participant. Because masking of research
assessors to treatment allocation after randomisation was impractical, we relied on participant ratings
to keep observer bias to a minimum.
Outcomes
The two participant-rated primary outcome measures were the Chalder fatigue questionnaire (Likert
scoring 0, 1, 2, 3; range 0–33; lowest score is least fatigue)  and the short form-36 physical function
subscale (version 2; range 0–100; highest score is best function).  Before outcome data were
examined, we changed the original bimodal scoring of the Chalder fatigue questionnaire (range 0–11) to
Likert scoring to more sensitively test our hypotheses of effectiveness. The two primary outcome
measures  are valid and reliable and have been used in previous trials.
For safety outcomes, we included non-serious adverse events, serious adverse events, serious adverse
reactions to trial treatments, serious deterioration, and active withdrawals from treatment.  Adverse
events were defined as any clinical change, disease, or disorder reported, whether or not related to
treatment. Three scrutinisers (two physicians and one liaison psychiatrist who all specialised in chronic
fatigue syndrome) reviewed all adverse events and reactions, independently from the trial team, and
were masked to treatment group, to establish whether they were serious adverse events. Scrutinisers
were then unmasked to treatment allocation to establish if any serious adverse events were serious
adverse reactions. Serious deterioration in health was defined as any of the following outcomes: a short
form-36 physical function score decrease of 20 or more between baseline and any two consecutive
assessment interviews;  scores of much or very much worse on the participant-rated clinical global
impression change in overall health scale at two consecutive assessment interviews;  withdrawal from
treatment after 8 weeks because of a participant feeling worse; or a serious adverse reaction.
For secondary outcomes, we used the clinical global impression scale to assess change from baseline in
overall health.  This 7-point scale was condensed into three categories: negative change (very much
worse or much worse), minimum change (a little worse, no change, or a little better), and positive
change (much better or very much better). We also assessed overall disability with the work and social
adjustment scale,  6-min walking ability (distance in m walked),  Jenkins scale score for disturbed
sleep,  hospital anxiety and depression scale score,  number of chronic fatigue syndrome symptoms,
and individual symptoms of postexertional malaise and poor concentration or memory, as in the
international criteria.  These secondary outcomes were a subset of those specified in the protocol,
selected in the statistical analysis plan as most relevant to this report. After participants had been told
their treatment allocation, but before treatment began, they rated how logical their proposed treatment
seemed and how confident they were that it would help them (5-point Likert scale with moderately and
extremely condensed into a positive response to help with interpretation). At 52 weeks, participants
rated satisfaction with treatment received on a 7-point scale, condensed into three categories to aid
set when necessary to avoid overexertion, which eventually aimed at 30 min of light exercise five
times a week. When this rate was achieved, the intensity and aerobic nature of the exercise was
gradually increased, with participant feedback and mutual planning. The most commonly chosen
exercise was walking. The therapy manual was based on that used in previous trials.  GET was
delivered by physiotherapists and one exercise physiologist (webappendix p 1).
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interpretation (satisfied, neutral, or dissatisfied).
Statistical analysis
We calculated sample sizes assuming 60% response to CBT at 52 weeks, 50% response to GET, 25%
response to APT, and 10% response to SMC.  We assumed APT to be at least as effective as in
previous trials of relaxation and flexibility therapies.  For a two-sided test with 5% significance
level and 90% power, we calculated that the number of participants needed to compare SMC with APT
was 135, SMC with GET was 80, and SMC with CBT was 40. We increased group size to 150 per group
to allow for 10% dropout, to provide equality between groups, and for secondary analyses. The
statistical analysis plan was finalised, including changes to the original protocol, and was approved by
the trial steering committee and the data monitoring and ethics committee before outcome data were
examined.
We used continuous scores for primary outcomes to allow a more straightforward interpretation of the
individual outcomes, instead of the originally planned composite measures (50% change or meeting a
threshold score).  We prorated primary outcomes scales only when there were at most two items
per scale missing (nine participants for Chalder fatigue questionnaire and 11 for short form-36).
Prorating involved calculating the mean value of the item scores present and replacing the missing
values with that score.
We summarised continuous variables with mean (SD) or median (IQR) and categorical variables with
frequencies and proportions. Differentiation of treatment compared independent ratings of therapy
sessions with actual treatment. We calculated the inter-rater reliability (κ and 95% CI) between the two
assessors. We used Kruskal-Wallis tests for comparisons of therapy received, therapeutic alliance, and
manual adherence. We compared categorical variables with Fisher's exact test.
A clinically useful difference between the means of the primary outcomes was defined as 0·5 of the SD
of these measures at baseline,  equating to 2 points for Chalder fatigue questionnaire and 8 points for
short form-36. A secondary post-hoc analysis compared the proportions of participants who had
improved between baseline and 52 weeks by 2 or more points of the Chalder fatigue questionnaire, 8 or
more points of the short form-36, and improved on both. In another post-hoc analysis, we compared
the proportions of participants who had scores of both primary outcomes within the normal range at 52
weeks. This range was defined as less than the mean plus 1 SD scores of adult attendees to UK general
practice of 14·2 (+4·6) for fatigue (score of 18 or less) and equal to or above the mean minus 1 SD
scores of the UK working age population of 84 (−24) for physical function (score of 60 or more).
We estimated differences between treatment groups for both primary outcomes with mixed linear
regression models with Kenward-Roger adjusted standard errors. Covariates were treatment group,
baseline value of outcome, time, and stratification factors (centre, present depressive disorder, and
alternative criteria for chronic fatigue syndrome and myalgic encephalomyelitis; all as stratified at
entry). Time by treatment interaction terms were included to allow extraction of contrasts at 52 weeks.
Models for the primary outcomes and the clinical global impression incorporated random intercepts
and slopes over time by participant and main health-care practitioner (doctor or therapist who saw the
participant most frequently, or, if equal, the first practitioner to see the participant) to allow for
clustering of outcomes within practitioner. We calculated intraclass correlation coefficients, adjusted for
baseline outcomes, using one-way random effects analysis of covariance at 52 weeks within every
treatment group. Unadjusted and Bonferroni corrected p values are provided for five comparisons for
both primary outcomes. Comparisons of primary outcomes across treatment groups by alternative
criteria for chronic fatigue syndrome and myalgic encephalomyelitis, and comorbid depressive disorder
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included the treatment by criteria or disorder interaction terms. Because some errors were made in
stratification at randomisation, we used true status variables rather than status at stratification as
covariates.
We calculated adverse event and reaction rates by dividing the number of events by person-years of
follow-up multiplied by 100, and compared rate differences (95% CI) between treatment groups.
We analysed changes in clinical global impression scale using binary logistic generalised estimating
equations regression with an exchangeable working correlation and bootstrapped standard errors. We
analysed the number of chronic fatigue syndrome symptoms with ordinary least squares linear
regression, and the presence of specific chronic fatigue syndrome symptoms with logistic regression. We
analysed secondary outcomes with mixed linear regression models with random participant intercepts
and slopes over time, apart from the walking test, which had random intercepts only. Covariates in the
models were otherwise the same, except for clinical global impression (not measured at baseline) and
chronic fatigue syndrome symptoms (measured only at 52 weeks).
We excluded participants from the intention-to-treat population for whom we had no primary outcome
data in the final analysis, which used restricted maximum likelihood. The per-protocol analysis
excluded participants who were ineligible after randomisation, treated at a second centre, or did not
received adequate treatment, adjusting for actual stratification factors. Statistical analyses were done
with Stata version 10, SAS version 9.1, and SPSS version 18.
This trial is registered at http://isrctn.org, number ISRCTN54285094.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. All named authors had access to the data, commented on drafts,
and approved the final report. Members of the writing group had responsibility for submitting the
report, and PDW had final responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial profile. Briefly, 898 (28%) of 3158 patients screened for eligibility progressed to
baseline screening and 641 (71%) participants were recruited (figure 1). The commonest reason for
exclusion from initial clinician screening was failure to meet Oxford criteria for chronic fatigue
syndrome (1011 participants). 745 (74%) of these excluded patients did not have chronic fatigue
syndrome and the rest did not meet Oxford criteria despite having clinician-diagnosed chronic fatigue
syndrome. Table 1 shows baseline characteristics of participants, which were much the same between
groups, apart from a shorter duration of illness in the SMC group than was noted in the other groups.
33 (5%) of 640 participants were lost to follow-up, but rates did not differ between groups (p=0·30; 
figure 1). Ten of these 33 participants had no outcome data, and were therefore excluded from the final
analysis. Primary outcomes were assessed at the time of dropout for three participants and included in
the final analyses. Research assessors recorded primary outcomes (eg, dictated over the telephone) on
74 (4%) of 1920 occasions.
Table 2 shows details of treatments received. Participants allocated to SMC alone received more
sessions, but there were no differences in the number of SMC sessions or therapy sessions received
between the other three groups. There were no differences between groups in the proportions who had
received adequate treatment (85% or more in every group). Participants' expectations were high for
APT and GET, but lower for CBT and SMC (table 2). Most of those who received a therapy were
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satisfied with treatment (82% or more for the three therapies), but fewer were satisfied with SMC
(50%). Number of treatment dropouts did not differ between groups (p=0·50; table 2). The two
independent therapy assessors rated 58 (94%) of 62 and 57 (92%) of 62 therapy sessions as being the
one allocated; only one (2%) session was rated by both assessors as different from that allocated. The
inter-rater reliability (κ; 95% CI) was 0·86 (0·75–0·97). The independent assessors were unmasked in
25 (40%) of 62 sessions that they listened to. All three therapies were rated as adhering well to the
manuals. Therapeutic alliance median scores were high and the same across therapies.
Table 3 shows baseline and outcomes data, and figure 2 shows profiles for the primary outcomes. In the
final-adjusted models (figure 3), participants had less fatigue and better physical function after CBT
and GET than they did after APT or SMC alone. Outcomes after APT were no better than they were
after SMC. Allowing for clustering effects caused by participants attending the same main practitioner
had little effect on these results; intraclass correlation coefficients ranged from −0·02 to 0·11 for fatigue,
and −0·01 to 0·03 for physical function. Participant subgroups meeting international criteria for chronic
fatigue syndrome, London criteria for myalgic encephalomyelitis, and depressive disorder criteria did
not differ in the pattern of treatment effects (figure 2; all p  were non-significant).
64 (42%) of 153 participants in the APT group improved by at least 2 points for fatigue and at least 8
points for physical function at 52 weeks, compared with 87 (59%) of 148 participants for CBT, 94 (61%)
of 154 participants for GET, and 68 (45%) of 152 participants for SMC. More participants improved
after CBT compared with APT (p=0·0033) or SMC (p=0·0149), and more improved with GET compared
with APT (p=0·0008) or SMC (p=0·0043); APT did not differ from SMC (p=0·61; webappendix p 2).
25 (16%) of 153 participants in the APT group were within normal ranges for both primary outcomes at
52 weeks, compared with 44 (30%) of 148 participants for CBT, 43 (28%) of 154 participants for GET,
and 22 (15%) of 152 participants for SMC. More participants were within normal ranges after CBT than
APT (p=0·0057) or SMC (p=0·0014), and more were within normal ranges with GET compared with
APT (p=0·0145) or SMC (p=0·0040); APT did not differ from SMC (p=0·65).
Webappendix p 3 shows the per-protocol analysis. Differences between treatments were very similar to
those of the final analysis, but magnitude was almost always higher in the per-protocol analysis.
Table 4 shows safety outcomes. Non-serious adverse events were common. Participants who received
CBT reported slightly fewer such events than did those in the APT (p=0·0081) and SMC (p=0·0016)
groups. Serious adverse events and serious deterioration were uncommon; serious adverse reactions
were rare. There were more serious adverse events in the GET group than there were in the SMC group
(p=0·0433). Rates of serious adverse reactions and serious deterioration did not differ between
treatment groups. Webappendix pp 4–5 shows a summary of serious adverse events and serious
adverse reactions.
Table 5 shows data for the clinical global impression scale ratings. At 52 weeks, more patients rated
themselves as much better or very much better in overall health after CBT and GET than did after APT
and SMC. A minority (≤9% in every group) rated themselves as much worse or very much worse, which
did not differ between groups.
Table 6 shows other secondary outcomes. At 52 weeks, participants in the CBT and GET groups had
better outcomes than did participants in the APT and SMC groups for work and social adjustment
scores, sleep disturbance, and depression (with the one exception that GET was no different from APT
for depression). Anxiety was lower after CBT and GET than it was after SMC, but not than after APT.
There were fewer chronic fatigue syndrome symptoms after CBT than there were after SMC. Poor
interactions
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concentration and memory did not differ between groups. Postexertional malaise was lower after CBT
and GET than it was after APT and SMC. 6-min walking distances were greater after GET than they
were APT and SMC, but were no different after CBT compared with APT and SMC. There were no
differences in any secondary outcomes between APT and SMC groups (webappendix pp 6–9).
Discussion
When added to SMC, CBT and GET had greater success in reducing fatigue and improving physical
function than did APT or SMC alone. APT was no better than was SMC alone. Our findings were much
the same for participants meeting the different diagnostic criteria for chronic fatigue syndrome and for
myalgic encephalomyelitis, for those with depressive disorder, and after allowing for clustering effects.
Other secondary outcomes showed a very similar pattern. There were no important differences in safety
outcomes between treatment options.
Mean differences between groups on primary outcomes almost always exceeded predefined clinically
useful differences for CBT and GET when compared with APT and SMC. In all comparisons of the
proportions of participants who had either improved or were within normal ranges for these outcomes,
CBT and GET did better than did APT or SMC alone. No more than 30% of participants were within
normal ranges for both outcomes and only 41% rated themselves as much better or very much better in
their overall health. We suggest that these findings show that either CBT or GET, when added to SMC,
is an effective treatment for chronic fatigue syndrome, and that the size of this effect is moderate (panel
2).
Panel 2
Research in context
Systematic review
We searched the PubMed and Cochrane Library databases up to Nov 6, 2010, without language
restrictions for full papers reporting randomised controlled trials, systematic reviews, and meta-
analyses with the search terms “chronic fatigue syndrome”, “myalgic encephalomyelitis”, “myalgic
encephalopathy” and “cognitive behaviour therapy”, “exercise”, “pacing”. We excluded trials of
adolescents, education, and group interventions. Our search identified the two most recent
systematic reviews,  two meta-analyses,  and two additional trials  that were not included in
these reviews. The reviews and meta-analyses concluded that cognitive behaviour therapy and
graded exercise therapy are moderately effective treatments for chronic fatigue syndrome, and that
limitations of previous trials included small size, an absence of data for safety outcomes, and high
dropout rates.  The findings from these studies concur with the UK National Institute for Health
and Clinical Excellence guidelines.
Interpretation
In the pacing, graded activity, and cognitive behaviour therapy: a randomised evaluation (PACE)
trial, we affirm that cognitive behaviour therapy and graded exercise therapy are moderately
effective outpatient treatments for chronic fatigue syndrome when added to specialist medical care,
as compared with adaptive pacing therapy or specialist medical care alone. Findings from PACE also
allow the following interpretations: adaptive pacing therapy added to specialist medical care is no
more effective than specialist medical care alone; our findings apply to patients with differently
defined chronic fatigue syndrome and myalgic encephalomyelitis whose main symptom is fatigue;
4,5 6,7 34,35
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Our conclusions are supported by secondary outcomes, as both CBT and GET provided greater
improvements than did APT and SMC for most outcomes. The objective walking test favoured GET over
CBT, whereas CBT provided the largest reduction in depression. The comparatively greater reduction in
postexertional malaise with both CBT and GET compared with the other two treatments is notable,
since the risk of exacerbation of this symptom is commonly given as a reason to avoid treatments such
as GET. The 47% prevalence of mood and anxiety disorders at baseline was much the same as that
noted in previous trials in secondary care (38–56%).  The equivalent use of antidepressants in
the treatment groups implies that the differences in outcomes are unlikely to be attributable to these
drugs.
There were no differences between groups in the proportions with serious deterioration or serious
adverse reactions. The increased rate of serious adverse events with GET compared with SMC is
unlikely to be important because serious adverse events were not thought by the independent
scrutinisers to be related to treatment. Consequently, if these treatments are delivered as described, by
similarly qualified and trained clinicians, patients need not be concerned about safety.
The finding that APT when added to SMC was no more effective than SMC alone was contrary to our
initial hypothesis. This finding might in part be caused by greater improvement after SMC than was
expected. Suboptimum delivery of APT is an unlikely explanation because APT therapists were the most
experienced; the therapeutic alliance and the adherence to manuals were rated highly in this group and
participant satisfaction did not differ from that for other therapies. Since participants' confidence that
APT would help them was much the same as for GET, and greater than that for CBT, they were unlikely
to have been biased by negative expectations. The fundamental difference between APT and both CBT
and GET is that APT encourages adaptation to the illness,  whereas CBT and GET encourage
gradual increases in activity with the aim of ameliorating the illness.  Our results do not support
pacing, in the form of APT, as a first-line therapy for chronic fatigue syndrome.
We plan to report relative cost-effectiveness of the treatments, their moderators and mediators,
whether subgroups respond differently, and long-term follow-up in future publications. Our finding
that studied treatments were only moderately effective also suggests research into more effective
treatments is needed. The effectiveness of behavioural treatments does not imply that the condition is
psychological in nature.
Our findings were strengthened by the small numbers of dropouts, high rates of acceptance of the
treatments, use of manual-defined treatments provided by competent clinicians, high rates of
participant satisfaction, adherence to manuals, and therapeutic alliance. The PACE findings can be
generalised to patients who also meet alternative diagnostic criteria for chronic fatigue syndrome  and
myalgic encephalomyelitis  but only if fatigue is their main symptom.
Our trial had limitations. We excluded patients unable to attend hospital. Our results apply to patients
referred to secondary care. SMC is not the same as usual medical care that might be provided by a
family doctor; this study was not designed to compare SMC with usual medical care. Although more
than 3000 patients attending clinics had to be screened to identify the 641 recruited, the commonest
reason for exclusion at screening was not having chronic fatigue syndrome. We chose conventional
criteria for defining clinically useful differences between treatments, although other thresholds could
have been chosen.  SMC was not as closely monitored or supervised as the other therapies, and
participants receiving SMC alone had more sessions than did those in the therapy groups; this is
and all four treatments tested are safe.
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unlikely to have affected comparisons between the groups. Masking of participants or clinicians to
treatment allocation was not possible, and research assessors were also not masked. Primary outcomes
were subjective and rated by participants. While this avoided investigator bias, it could be subject to
other biases. Although participant-rated outcome measures could have been affected by expectations of
treatment, which were highest for APT and GET, CBT was one of the two most effective treatments
despite lower expectations.
Findings from the PACE trial suggest that individually delivered CBT and GET, when added to SMC, are
more effective and as safe as APT added to SMC or SMC alone. Patients attending secondary care with
chronic fatigue syndrome should be offered individual CBT or GET, alongside SMC.
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CONSORT trial profile
CFS=chronic fatigue syndrome. APT=adaptive pacing therapy. CBT=cognitive behaviour therapy. GET=graded exercise
therapy. SMC=specialist medical care alone. The numbers of participants per centre ranged from 63 to 135.
Figure 2
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Physical function subscale and fatigue questionnaire scores by treatment group
Data are unadjusted means (95% CI). p  is the p-value of the interaction between treatment and criteria or
disorder from the adjusted model. CFS=chronic fatigue syndrome. ME=myalgic encephalomyelitis. (A–D) Lowest fatigue
interaction
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score is best. (E–H) Highest physical function score is best.
Figure 3
Primary outcome treatment differences for fatigue (A) and physical function (B) at 52 weeks
(A) Negative values for fatigue favour the first treatment group in each pair of comparisons. (B) Positive values for
physical function favour the first treatment group in each pair of comparisons. APT=adaptive pacing therapy.
SMC=specialist medical care. CBT=cognitive behaviour therapy. GET=graded exercise therapy.
Table 1
Baseline demographics and clinical characteristics
Adaptive pacing
therapy (n=159)
Cognitive behaviour
therapy (n=161)
Graded exercise
therapy (n=160)
Specialist medical
care alone (n=160)
Overall
(n=640)
Demographic data
Age (years) 39 (11) 39 (12) 39 (12) 37 (11) 38 (12)
Female 121 (76%) 129 (80%) 123 (77%) 122 (76%) 495 (77%)
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White 146 (92%) 151 (94%) 148 (93%) 150 (94%) 595 (93%)
Any ME group
membership
31 (19%) 26 (16%) 25 (16%) 23 (14%) 105 (16%)
Clinical data
International CFS criteria
As randomised 99 (62%) 100 (62%) 98 (61%) 100 (63%) 397 (62%)
Actual 107 (67%) 106 (66%) 106 (66%) 108 (68%) 427 (67%)
London ME criteria
As randomised 89 (56%) 90 (56%) 89 (56%) 89 (56%) 357 (56%)
Actual 81 (51%) 84 (52%) 84 (53%) 80 (50%) 329 (51%)
Any depressive disorder
As randomised 55 (35%) 55 (34%) 54 (34%) 55 (34%) 219 (34%)
Actual 54 (34%) 52 (32%) 54 (34%) 53 (33%) 213 (33%)
Any psychiatric
disorder
75 (47%) 75 (47%) 73 (46%) 77 (48%)
300
(47%)
Duration of
illness
(months)
33 (16–69) 36 (16–104) 35 (18–67) 25 (15–57)
32 (16–
68)
Body-mass
index (kg/m )
25·9 (5·5) 25·4 (5·2) 25·5 (4·6) 25·1 (4·5) 25·5 (5·0)
Data are mean (SD), n (%), or median (IQR). ME=myalgic encephalomyelitis. CFS=chronic fatigue
syndrome.
Psychiatric disorders included any depressive disorder and any anxiety disorder, including phobias,
obsessive-compulsive disorder, and post-traumatic stress disorder.
Table 2
Treatment details
Adaptive pacing
therapy (n=159)
Cognitive
behaviour therapy
(n=161)
Graded exercise
therapy (n=160)
Specialist medical
care alone (n=160)
p
value
Treatment received
Therapy sessions
attended
13 (12–15) 14 (12–15) 13 (12–14) .. 0·17
Specialist medical
care sessions
attended
3 (3–4) 3 (3–4) 3 (3–4) 5 (3–6) 0·0001
Adequate treatment 143 (90%) 140 (87%) 136 (85%) 142 (89%) 0·56
Antidepressant at
baseline
63 (40%) 57 (35%) 74 (46%) 66 (41%) ..
Antidepressant at 24
weeks
53 (34%) 45 (29%) 61 (40%) 60 (39%) 0·19
Antidepressant at 52
12
13
*
2
*
*
†
‡
§
¶
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weeks
41 (27%) 47 (31%) 48 (31%) 61 (39%) 0·11
Hypnotic at baseline 6 (4%) 9 (6%) 6 (4%) 5 (3%) ..
Hypnotic at 24
weeks
3 (2%) 7 (5%) 5 (3%) 6 (4%) 0·61
Hypnotic at 52
weeks
5 (3%) 4 (3%) 3 (2%) 7 (5%) 0·62
Non-allocated
treatment
8 (5%) 4 (3%) 7 (4%) 22 (14%) 0·0005
Dropouts from
treatment
11 (7%) 17 (11%) 10 (6%) 14 (9%) 0·50
Views before treatment
Treatment is logical 134 (84%) 115 (71%) 135 (84%) 79 (49%) <0·0001
Confident about
treatment
114 (72%) 91 (57%) 112 (70%) 65 (41%) <0·0001
Views after treatment
Satisfied with
treatment
128 (85%) 117 (82%) 126 (88%) 76 (50%) <0·0001
Dissatisfied with
treatment
4 (3%) 7 (5%) 2 (1%) 17 (11%) 0·0010
Therapeutic alliance 6·5 (6·0–6·5) 6·5 (5·5–6·8) 6·5 (5·5–7·0) .. 0·96
Adherence to
manual
6·0 (6·0–6·5) 6·0 (5·0–6·5) 6·5 (6·0–6·5) .. 0·35
Data are median (IQR) or n (%).
p values across all groups.
86% of sessions were received face-to-face and 14% by telephone.
94% of sessions were received face-to-face and 6% by telephone.
Adequate treatment was ten or more sessions of therapy or three or more sessions of specialist medical
care alone.
Percentages exclude missing data.
Scored 1–7 (1=poor, 7=excellent).
Scored 1–7 (1=not at all, 7=very much so).
Table 3
Primary outcomes of fatigue and physical function
Fatigue Physical function
Adaptive
pacing
therapy
Cognitive
behaviour
therapy
Graded
exercise
therapy
Specialist
medical
care alone
Adaptive
pacing
therapy
Cognitive
behaviour
therapy
Graded
exercise
therapy
Specialist
medical
care alone
Baseline
28·5 (4·0);
n=159
27·7 (3·7);
n=161
28·2 (3·8);
n=160
28·3 (3·6);
n=160
37·2
(16·9);
n=159
39·0 (15·3);
n=161
36·7
(15·4);
n=160
39·2 (15·4);
n=160
¶
¶
¶
¶
¶
‖
**
*
†
‡
§
¶
‖
**
* †
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12 weeks
24·2 (6·4);
n=153
23·6 (6·5);
n=153
22·8 (7·5);
n=153
24·3 (6·5);
n=154
41·7
(19·9);
n=153
51·0 (20·7);
n=153
48·1
(21·6);
n=153
46·6 (20·4);
n=154
24 weeks
23·7 (6·9);
n=155
21·5 (7·8);
n=148
21·7 (7·1);
n=150
24·0 (6·9);
n=152
43·2
(21·4);
n=155
54·2 (21·6);
n=148
55·4
(23·3);
n=150
48·4 (23·1);
n=152
52 weeks
23·1 (7·3);
n=153
20·3 (8·0);
n=148
20·6 (7·5);
n=154
23·8 (6·6);
n=152
45·9
(24·9);
n=153
58·2 (24·1);
n=148
57·7
(26·5);
n=154
50·8 (24·7);
n=152
Mean difference
(95% CI) from
SMC (52 weeks)
−0·7 (−2·3
to 0·9)
−3·4 (−5·0
to −1·8)
−3·2 (−4·8
to −1·7)
..
−3·4 (−8·4
to 1·6)
7·1 (2·0 to
12·1)
9·4 (4·4 to
14·4)
..
Unadjusted p
values
0·38 0·0001 0·0003 .. 0·18 0·0068 0·0005 ..
Bonferroni
adjusted p values
0·99 0·0006 0·0013 .. 0·89 0·0342 0·0025 ..
Mean difference
(95% CI) from
APT (52 weeks)
..
−2·7 (−4·4
to −1·1)
−2·5 (−4·2
to −0·9)
.. ..
10·5 (5·4 to
15·6)
12·8 (7·7
to 17·9)
..
Unadjusted p
values
.. 0·0027 0·0059 .. .. 0·0002 <0·0001 ..
Bonferroni
adjusted p values
.. 0·0136 0·0294 .. .. 0·0012 0·0002 ..
Number improved
from baseline
99 (65%) 113 (76%) 123 (80%) 98 (65%) 75 (49%) 105 (71%) 108 (70%) 88 (58%)
Data are mean scores (SD) or n (%), unless otherwise stated. Comparisons of differences across groups
made at 52 weeks are from the final adjusted models, so are slightly different from unadjusted values. p
values for comparisons are unadjusted, with Bonferroni values adjusted for five comparisons for every
primary outcome.
Chalder fatigue questionnaire (range 0–33, 0=best).
Short form-36 physical function subscale score (range 0–100, 100=best).
Participants improved from baseline by two or more points for fatigue and eight or more for physical
function.
Table 4
Safety outcomes
Adaptive pacing
therapy (n=159)
Cognitive behaviour
therapy (n=161)
Graded exercise
therapy (n=160)
Specialist medical
care alone (n=160)
Non-serious adverse events 949 848 992 977
Participants with non-
serious adverse events
152 (96%) 143 (89%) 149 (93%) 149 (93%)
Non-serious adverse events
per 100 person-years
597 (559–636) 527 (492–563) 620 (582–660) 611 (573–650)
‡
* 15
† 16
‡
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Serious adverse events 16 8 17 7
Participants with serious
adverse events
15 (9%) 7 (4%) 13 (8%) 7 (4%)
Serious adverse events per
100 person-years
10·1 (5·8–16·3) 5·0 (2·2–9·8) 10·6 (6·2–17·0) 4·4 (1·8–9·0)
Serious adverse reactions 2 4 2 2
Participants with serious
adverse reactions
2 (1%) 3 (2%) 2 (1%) 2 (1%)
Serious adverse reactions
per 100 person-years
1·3 (0·2–4·5) 2·5 (0·7–6·4) 1·3 (0·2–4·5) 1·3 (0·2–4·5)
Serious deterioration
(composite)
13 (8%) 14 (9%) 10 (6%) 15 (9%)
Physical functioning
reduction
7 (4%) 5 (3%) 5 (3%) 6 (4%)
PCGI worse 5 (3%) 7 (4%) 1 (<1%) 10 (6%)
Withdrawn due to
worsening
3 (2%) 0 2 (1%) 1 (<1%)
Serious adverse reactions 2 (1%) 3 (2%) 2 (1%) 2 (1%)
Differences in serious deterioration
Comparison with specialist
medical care
−1·2%; p=0·71 −0·7%; p=0·83 −3·1%; p=0·30 ..
Comparison with adaptive
pacing therapy
.. 0·5%; p=0·87 −1·9%; p=0·51 ..
Data are n, n (%), or rate (95% CI), unless otherwise stated. Adverse events were considered serious
when they involved death, hospital admission, increased severe and persistent disability, self-harm,
were life-threatening, or required an intervention to prevent one of these. There were no suspected
unexpected serious adverse reactions. PCGI=participant-rated clinical global impression.
Serious deterioration composite is either of a short form-36 physical function subscale score reduction
at two consecutive visits, a PCGI score of much worse or very much worse at two consecutive visits,
withdrawal from treatment due to explicit worsening, or a serious adverse reaction; the numbers
withdrawn from treatment due to worsening is a subset of all those withdrawing from treatment shown
in table 2.
Table 5
Participant-rated clinical global impression of change in overall health
Adaptive pacing
therapy (n=159)
Cognitive behaviour
therapy (n=161)
Graded exercise
therapy (n=160)
Specialist medical
care alone (n=160)
Change from baseline
12 weeks 153 (96%) 153 (95%) 151 (94%) 151 (94%)
Positive change 20 (13%) 32 (21%) 37 (25%) 7 (5%)
Minimum change 126 (82%) 113 (74%) 111 (74%) 133 (88%)
Negative change 7 (5%) 8 (5%) 3 (2%) 11 (7%)
*
*
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24 weeks 155 (97%) 149 (93%) 148 (93%) 151 (94%)
Positive change 37 (24%) 56 (38%) 54 (37%) 28 (19%)
Minimum change 111 (72%) 82 (55%) 89 (60%) 107 (71%)
Negative change 7 (5%) 11 (7%) 5 (3%) 16 (11%)
52 weeks 153 (96%) 147 (91%) 152 (95%) 152 (95%)
Positive change 47 (31%) 61 (41%) 62 (41%) 38 (25%)
Minimum change 96 (63%) 77 (52%) 80 (53%) 100 (66%)
Negative change 10 (7%) 9 (6%) 10 (7%) 14 (9%)
Odds ratio (positive change vs negative or minimum changes)
Compared with
specialist medical care
1·3 (0·8–2·1); p=0·31 2·2 (1·2–3·9); p=0·011
2·0 (1·2–3·5);
p=0·013
..
Compared with
adaptive pacing
therapy
.. 1·7 (1·0–2·7); p=0·034
1·5 (1·0–2·3);
p=0·028
..
Data are n (%) or odds ratio (95% CI). Comparisons made at 52 weeks were taken from the final
adjusted models. Positive change was defined as very much better or much better. Minimum change
was defined as a little better, no change, or a little worse. Negative change was defined as much worse
or very much worse.
Table 6
Secondary outcomes
Adaptive pacing
therapy (n=159)
Cognitive behaviour
therapy (n=161)
Graded exercise
therapy (n=160)
Specialist medical
care alone (n=160)
Work and social
adjustment scale
150 (94%) 143 (89%) 144 (90%) 151 (94%)
Baseline score 27·9 (6·1) 27·4 (6·2) 27·3 (6·3) 26·9 (6·7)
52-week score 24·5 (8·8) 21·0 (9·6) 20·5 (9·4) 23·9 (9·2)
Comparison with SMC 0·1; p=0·93 −3·6; p=0·0001 −3·2; p=0·0006 ..
Comparison with APT .. −3·7; p=0·0001 −3·3; p=0·0004 ..
6-min walking test 111 (70%) 123 (76%) 110 (69%) 118 (74%)
Baseline distance (m) 314 (90) 333 (86) 312 (87) 326 (95)
52-week distance (m) 334 (117) 354 (106) 379 (100) 348 (108)
Comparison with SMC −5·7; p=0·55 −1·5; p=0·87 35·3; p=0·0002 ..
Comparison with APT .. 4·2; p=0·65 41·0; p<0·0001 ..
Jenkins sleep scale 150 (94%) 143 (89%) 144 (90%) 151 (94%)
Baseline score 12·1 (4·9) 12·5 (4·9) 11·7 (4·3) 12·4 (5·0)
52-week score 10·6 (4·8) 9·9 (5·3) 9·0 (4·8) 11·0 (5·0)
Comparison with SMC −0·1; p=0·76 −1·1; p=0·0216 −1·4; p=0·0024 ..
Comparison with APT .. −0·9; p=0·0466 −1·3; p=0·0062 ..
HADS depression scale 149 (94%) 143 (89%) 144 (90%) 151 (94%)
Baseline score 8·1 (3·9) 8·3 (3·7) 8·2 (3·6) 8·0 (3·9)
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52-week score 7·2 (4·5) 6·2 (3·7) 6·1 (4·1) 7·2 (4·7)
Comparison with SMC −0·6; p=0·11 −1·4; p=0·0003 −1·1; p=0·0035 ..
Comparison with APT .. −0·8; p=0·0382 −0·5; p=0·18 ..
HADS anxiety scale 149 (94%) 143 (89%) 144 (90%) 149 (93%)
Baseline score 8·1 (4·2) 8·1 (4·3) 8·0 (4·2) 7·9 (4·3)
52-week score 7·5 (4·2) 6·8 (4·2) 7·1 (4·5) 8·0 (4·4)
Comparison with SMC −0·7; p=0·0713 −1·4; p=0·0003 −1·0; p=0·0142 ..
Comparison with APT .. −0·7; p=0·0671 −0·3; p=0·50 ..
Chronic fatigue
syndrome symptom
count
151 (95%) 145 (90%) 144 (90%) 149 (93%)
Baseline 4·8 (1·8) 4·6 (1·8) 4·6 (1·8) 4·7 (1·7)
52 week 3·8 (2·3) 3·4 (2·3) 3·4 (2·5) 3·9 (2·2)
Comparison with SMC −0·1; p=0·62 −0·5; p=0·0329 −0·4; p=0·0916 ..
Comparison with APT .. −0·4; p=0·0986 −0·3; p=0·23 ..
Poor concentration or
memory
151 (95%) 145 (90%) 144 (90%) 149 (93%)
Baseline (n [%] with
symptoms)
122 (77%) 117 (73%) 122 (76%) 115 (72%)
52 weeks (n [%] with
symptoms)
93 (59%) 73 (45%) 76 (48%) 90 (56%)
Comparison with SMC
Odds ratio 1·0;
p=0·97
Odds ratio 0·6;
p=0·0602
Odds ratio 0·7;
p=0·14
..
Comparison with APT ..
Odds ratio 0·6;
p=0·0629
Odds ratio 0·7;
p=0·15
..
Postexertional malaise 151 (95%) 145 (90%) 144 (90%) 149 (93%)
Baseline (n [%] with
symptoms)
134 (84%) 135 (84%) 131 (82%) 139 (87%)
52 weeks (n [%] with
symptoms)
100 (63%) 79 (49%) 71 (44%) 101 (63%)
Comparison with SMC
Odds ratio 1·0;
p=0·86
Odds ratio 0·6;
p=0·0254
Odds ratio 0·5;
p=0·0026
..
Comparison with APT ..
Odds ratio 0·6;
p=0·0380
Odds ratio 0·5;
p=0·0042
..
Data are number of completed questionnaires at 52 weeks (%), means (SD), or mean difference, unless
otherwise stated. Comparisons across treatment arms at 52 weeks are from the final adjusted models.
Webappendix pp 6–9 shows forest plots of mean differences (95% CI) and odds ratios (95% CI) for
comparisons between groups. APT=adaptive pacing therapy. SMC=specialist medical care alone.
HADS=hospital anxiety and depression scale.
